Deutsche Bank reiterates its Buy rating on Alexion ALXN and boosts its price target by $14 to $92 on a pipeline that should make for revenue growth in 2012.
Deutsche Bank says, "Alexion investing in pipeline - New TP $92 on STEC HUS & asfotase alfa. - 2012 is shaping up to be a year of revenue growth & increased R&D investment for Alexion. We see Soliris revenue growing as aHUS launch progresses. We see fruits of investment beginning to emerge in late 2013/2014 with launch of 1) Soliris in STEC HUS & kidney transplant & 2) asfotase alfa (Enobia acquisition) for hypophosphatasia (HPP). We are now including STEC HUS & asfotase alfa opportunities, which increases our TP to $92."
ALXN closed at $80.41 a share on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in